{"id":7262,"date":"2024-01-25T14:57:31","date_gmt":"2024-01-25T19:57:31","guid":{"rendered":"https:\/\/lifescivoice.com\/?p=7262"},"modified":"2024-01-25T14:57:33","modified_gmt":"2024-01-25T19:57:33","slug":"sanofi-snags-rare-drug-inbrx-101-in-a-bid-to-pioneer-biotech-advancements","status":"publish","type":"post","link":"https:\/\/lifescivoice.com\/sanofi-snags-rare-drug-inbrx-101-in-a-bid-to-pioneer-biotech-advancements\/","title":{"rendered":"Sanofi snags rare drug INBRX-101 in a bid to pioneer biotech advancements"},"content":{"rendered":"\n<p>Sanofi, the prominent pharmaceutical conglomerate, has undertaken a recent merger and acquisition (M&amp;A) venture. The company has inked an agreement to acquire Inhibrx, a U.S. biotech firm, for a sum of $1.7 billion. However, this acquisition takes a distinctive turn as Sanofi intends to retain only a specific asset, INBRX-101, and spin out the remaining three anticancer molecules into a novel publicly traded biotech entity.<\/p>\n\n\n\n<p>Sanofi has opted to procure Inhibrx for a price beneath the market value, settling at $30 per share, a figure below Inhibrx&#8217;s recent closing valuation of $33.33. This reduction aligns with Sanofi&#8217;s strategic decision to focus exclusively on INBRX-101, a human recombinant protein currently undergoing a pivotal registration-enabling trial for alpha-1 antitrypsin deficiency (AATD).&nbsp;<\/p>\n\n\n\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script>\n<ins class=\"adsbygoogle\" style=\"display:block; text-align:center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins>\n<script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script>\n\n\n\n<p>The deal structure encompasses the establishment of a new biotech company to house Inhibrx&#8217;s three anticancer molecules. This freshly formed entity, retaining the Inhibrx moniker, will commence operations with a commendable $200 million in cash and a debt-free status.&nbsp;<\/p>\n\n\n\n<p>The amalgamation of these components elevates the overall deal value to $2.2 billion. Following the deal&#8217;s conclusion, Sanofi will retain an 8% stake in the freshly minted Inhibrx biotech, under the continued leadership of CEO Mark Lappe.<\/p>\n\n\n\n<p>The focal point of this intricate maneuver, INBRX-101, is advancing through a clinical trial meticulously designed to assess its impact on serum functional AAT levels. Tailored to address alpha-1 antitrypsin deficiency, a rare genetic malady causing liver and lung complications, INBRX-101 offers a potential breakthrough by rectifying the deficiency without relying on plasma donations. Inhibrx envisions a substantial expansion of the AATD market with improved diagnosis, projecting a lucrative $4 billion opportunity in the coming years.<\/p>\n\n\n\n<script async=\"\" src=\"https:\/\/pagead2.googlesyndication.com\/pagead\/js\/adsbygoogle.js?client=ca-pub-3812572458252831\" crossorigin=\"anonymous\"><\/script>\n<ins class=\"adsbygoogle\" style=\"display:block; text-align:center;\" data-ad-layout=\"in-article\" data-ad-format=\"fluid\" data-ad-client=\"ca-pub-3812572458252831\" data-ad-slot=\"7669348015\"><\/ins>\n<script>\n     (adsbygoogle = window.adsbygoogle || []).push({});\n<\/script>\n\n\n\n<p>This strategic maneuver by Sanofi is not isolated in the pharmaceutical panorama. Recent months have witnessed a surge in merger and acquisition activities within the sector. The decision to selectively acquire assets aligns with Sanofi&#8217;s broader commitment to augmenting its drug development portfolio, especially in the realm of rare diseases.&nbsp;<\/p>\n\n\n\n<p>In the broader context of the pharmaceutical industry, this strategic acquisition mirrors a prevailing trend wherein companies are reshaping their portfolios to concentrate on specialized products. Houman Ashrafian, Sanofi&#8217;s Head of R&amp;D, highlighted the company&#8217;s unwavering dedication to differentiated and potentially best-in-class products, positioning INBRX-101 as a pivotal asset in this pursuit.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Sanofi, the prominent pharmaceutical conglomerate, has undertaken a recent merger and acquisition (M&amp;A) venture. The company has inked an agreement to acquire Inhibrx, a U.S. biotech firm, for a sum of $1.7 billion. However, this acquisition takes a distinctive turn as Sanofi intends to retain only a specific asset, INBRX-101, and spin out the remaining [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":7263,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26],"tags":[],"class_list":{"0":"post-7262","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-commercial"},"_links":{"self":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/7262","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/comments?post=7262"}],"version-history":[{"count":1,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/7262\/revisions"}],"predecessor-version":[{"id":7264,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/posts\/7262\/revisions\/7264"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media\/7263"}],"wp:attachment":[{"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/media?parent=7262"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/categories?post=7262"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifescivoice.com\/wp-json\/wp\/v2\/tags?post=7262"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}